CAR-T therapy vs BTK inhibitors in CLL treatment



Published
In this video, Marco Ruella, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses the excitement surrounding the future use of chimeric antigen receptor T-cell (CAR-T) therapy in the treatment of chronic lymphocytic leukemia (CLL). While CLL treatment has largely been dominated by small molecules, Dr Ruella highlights the challenges of these therapies, and the potential transition into treatment with CAR-T products. Following this, Dr Ruella briefly mentions some results from a 10-year follow-up on two CLL patients who received CD19 CAR-T therapy and are still in remission. To conclude, Dr Ruella emphasizes the promise that CAR-T therapy is showing as a long-term treatment for CLL, and the need for more clinical trials and research in this area. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Category
Health
Be the first to comment